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a  b  s  t  r  a  c  t
In October  2014,  after  over 12 months  of delay,  Poland  ﬁnally  implemented  directive
2011/24/EU  on  the application  of  patients’  rights  in  cross-border  healthcare.  The  imple-
menting  legislation  in the area  of  cost  reimbursement  and  prior  authorization  is  very
restrictive.  The  goal  is  to either  defer  the public  payer’s  expenses  into  the  future  or to
discourage  patients  from  seeking  care  abroad  or from  seeking  care  altogether.  The  Polish
government  and the  Ministry  of Health,  the  key  stakeholders  in  the  implementation  pro-
cess,  seemed  to overlook  the potential  monetary  beneﬁts  that  the  implementation  of  the
directive  could  bring,  for example,  by promoting  Poland  as  a destination  for health  tourism.
Other  stakeholders,  such  as patients  and  healthcare  providers,  had  no  real inﬂuence  on  the
policy  process.  So  far,  the number  of  applications  for  planned  treatment  abroad  has  been
very low  and  the  majority  of them  were  actually  turned  down  as they  did not  meet  the
formal  requirements.  This  number  is  likely  to remain  low  in  the  future  as  accessing  suchross-border health care
atients’ right
care is cumbersome  and  not  affordable  for many  patients.  Overall,  while  the  directive  does
not  aim to  encourage  patients  to  seek  cross-border  healthcare,  the  current  national  regu-
lations  in Poland  do not  seem  to  facilitate  access  to  cross-border  healthcare,  which  is  the
main  goal  of the directive.
© 2016  The  Author(s).  Published  by  Elsevier  Ireland  Ltd.  This  is an  open  access  article
Y-NC-Nunder  the  CC  B
. Introduction
In March 2011, directive 2011/24/EU on the application
f patients’ rights in cross-border healthcare was adopted
y a decision of the European Parliament and the Council
f the European Union (EU). The deadline for its implemen-
ation by the member states was set for 25 October, 2013.
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Poland, one of the main opponents of the directive, took
just over a year longer to transpose it into national legisla-
tion. In fact, one of the key factors that motivated the Polish
government to implement the directive was the increas-
ing number of lawsuits against the National Health Fund
(NHF) by patients demanding to be reimbursed for medical
treatment obtained abroad [13]. This article describes the
process of translating directive 2011/24/EU into Polish law;
the content of the Polish legislation transposing the direc-
tive, and the implications of this new law for the patients.
While the paper also describes differences between the
content of the national law and the content of the direc-
tive it does not assess the legality of the Polish provisions
in the light of the EU law.
en access article under the CC BY-NC-ND license (http://
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2. Policy background: receiving care in another EU
member state since Poland’s EU accession and since
coming to life of directive 2011/24/EU
As of its EU accession on 1 May, 2004, Poland has been
subject to EU regulations on the coordination of social secu-
rity systems (EC No 883/2004 and EC No 987/2009) [16].
By virtue of these regulations, socially insured Polish citi-
zens residing in another EU member state are fully entitled
to beneﬁts in-kind provided by health care institutions in
their place of residence at the expense of the Polish public
payer (NHF). Similarly, a person insured in another member
state who resides in Poland is fully entitled to services at
the expense of their public insurer. Articles 19–20 of EC No
883/2004 also provide for statutory coverage of treatment
received outside the state of residence or afﬁliation, i.e.
cross-border health care. Access to cross-border healthcare
is subject to certain conditions, such as prior authorization,
which depend on the type of care (emergency or planned).
Rulings of the European Court of Justice (ECJ) in cases
such as Kohll and Decker (1998) and Smits-Peerbooms
(2001) have created legal uncertainty for the member
states in terms of reimbursement of health services outside
the state where the patient is socially insured [3]. Several
attempts were made at the EU-level to put forward pol-
icy responses to this legal uncertainty. Although the initial
approach was to support European cooperation in this area
and a High Level Group on Health Services and Medical Care
was set up to this end in 2004, the European Commission
(EC) included healthcare services in its proposal for a ser-
vices directive—the so-called Bolkestein directive. In 2006,
after two years of heated policy debates, healthcare ser-
vices were ﬁnally excluded from the scope of this directive
and the EC announced it would put forward a speciﬁc legal
initiative for the health sector. After a lengthy and painful
policy process, the European Parliament and the Council
adopted the proposal for a directive in July 2008, with pro-
visions presented as ‘patients’ rights’ and not as ‘services’
as in the Bolkenstein directive.
Until the very last moment in the debate on the directive
in the Council, the choice of the providers to be covered by
the directive was the major outstanding issue. Many mem-
ber states preferred to exclude non-contractual healthcare
providers from the scope of the directive, since, in their
view, this would give rise to ‘reverse discrimination’. This
is because treatment of such providers is not reimbursed at
the national level, while they would have to be reimbursed
it in cross-border situations. This issue was at the core of
the Polish objection to the directive (see Section 4 below).
It was not until early-2011 that the European Parliament,
the Commission, and the Council ﬁnally agreed on a heav-
ily amended version—directive 2011/24/EU [3]. Besides
Poland, Austria, Portugal and Romania voted against it and
Slovakia abstained [16]. The key differences between the
rules of coordination and directive 2011/24/EU are sum-
marized in Table 1.
Each of the avenues of accessing healthcare abroad,
within the coordination system and under directive
2011/24/EU is governed by different laws and imposes var-licy 120 (2016) 1233–1239
ious obligations on the individuals who beneﬁt from them.
The choice of the avenue is at the discretion of the patient.
3. Implementation of directive 2011/24/EU in
Poland
In October 2014, Poland passed the law implementing
directive 2011/24/EU, which was  the amendment of the
Act on Healthcare Services Financed from Public Sources,
and set up a National Contact Point (NCP) for cross-border
healthcare within the NHF. Three executive regulations
implementing the provisions of this amendment were
issued by the Minister of Health in November 2014: on
the procedures for issuing authorization for reimburse-
ment and on pre-authorized care (regulation no 1551); on
the reimbursement application form (regulation no 1538);
and on the list of guaranteed beneﬁts requiring a prior-
authorization (regulation no 1545). The amendment and
the executive regulations came into force on 15 November,
2014 [9].
The amendment and the executive regulation no 1551
distinguish among three main sets of rules of ﬁnancing of
guaranteed beneﬁts provided outside the borders of Poland
concerning the cross-border care directive [9]:
(1) For beneﬁts already purchased: cost reimbursement
(see Fig. 1);
(2) For selected guaranteed beneﬁts exempted from (1):
prior-authorization (see Fig. 1);
(3) For guaranteed beneﬁts (treatment and diagnostic pro-
cedures) not currently provided in Poland (e.g. due
to the lack of adequate medical infrastructure): direct
payment to provider (see Fig. 2).
Fearing that a large number of people may  try to seek
healthcare abroad to avoid long waiting times in Poland,
access to healthcare abroad has been limited by a number
of restrictions [8]. We  summarize these barriers below.
3.1. Barrier 1: pre-authorization requirement
The ﬁrst barrier is the need to obtain a pre-authorization
for most healthcare services, including simple therapies
and diagnostics, such as pharmaceuticals included in the
national drug programmes, computer tomography and
magnetic resonance, for which there are long waiting times
in Poland [4]. A pre-authorization from the director of the
voievodeship branch of the NHF (in the voievodeship of
patient’s residence) is required for healthcare services that
require a hospital stay of at least one night regardless of the
type of service (i.e. almost any surgery will require a prior
approval of the NHF); treatment within national drug pro-
grammes listed in the 2011 Act on the Reimbursement of
Pharmaceuticals, Foodstuffs for Special Nutritional Use and
Medical Devices; and a number of therapies and diagnos-
tic tests: isotopic therapy; stereotactic teleradiotherapy;
hadronic teleradiotheraphy with the bundle of protons;
hyperbaric therapy; grafting the baclofen pump (if resis-
tant to pharmacological treatment); genetic examination;
positron emission tomography (PET); nuclear medicine
examinations; computer tomography; and magnetic res-
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Table  1
Key differences between the regulation on the coordination of social security systems and the directive on cross-border care.
Regulations on the coordination of social security systems Directive on cross-border care
Legal framework
Regulation (EC) No 883/2004 of the European Parliament and of the
Council of 29 April, 2004 on the coordination of social security systems
Cross-border healthcare directive 2011/24/EU of the European
Parliament and of the Council of 9 March, 2011 on the application of
patients’ rights in cross-border healthcareRegulation (EC) No 987/2009 of the European Parliament and of the
Council of 16 September, 2009 laying down the procedure for
implementing Regulation (EC) No 883/2004 on the coordination of social
security systems
Who  is covered?
EU/EFTA nationals who  are or who have been covered by the social
security legislation of one of EU/EFTA countries who  are living or staying
temporarily in another EU/EFTA country
EU nationals who  are or have been covered by the social security
legislation of one of the EU countries and who are living or staying
temporarily in an EU country
What is covered?
Medically necessary care during a temporary stay; full range of healthcare
beneﬁts covered within the statutory healthcare system of the country of
residence in case of permanent residence; planned treatment abroad;
healthcare beneﬁts related to the treatment of work accidents or
occupational diseases
All health beneﬁts covered within the statutory healthcare system of
the  country of origin
What documents are necessary to prove the right to healthcare?
European Health Insurance Card (EHIC) or Provisional Replacement
Certiﬁcate (PRC); E 112/S2 form (for planned treatment abroad)
Documents required by the legislation of the member state of origin in
case of prior-authorization and/or cost reimbursement
E106/E109/E120/E121/S1 form and a certiﬁcation issued on their basis(for
persons permanently residing in another EU or EFTA member state)
Which healthcare facilities and pharmacies can be used?
Only those facilities that provide services within the statutory healthcare
system of the country where services are provided
All facilities that are legally approved in the country where services are
provided (including facilities that provide healthcare services outside
of  the statutory healthcare system)
Which costs are covered?
Services covered by the statutory healthcare systems in the country where
services are provided; any statutory cost-sharing that is applied in that
system continues to apply
All costs must be initially covered out-of-pocket; costs will be
reimbursed up to the cost of the same service in the country of origin
Source: Based on Ref. [10].
Note: EFTA = European Free Trade Association.
Opinion
by a doctor:
NHF contracted
Regional Medical 
Consultants
NHF  Regional 
Branch Director
NHF  Regional 
Branch Director
NHF President
NHF  President
Guaranteed beneﬁts  requiring  pr ior  authorisa on
Guaranteed beneﬁts  NOT requiring  pr ior  authorisaon
Invesgaon
Applicaon
Applicaon
App eal
App eal
Decision
RefundDecision
Purchase
of
beneﬁts
Approx. 1 month
30/60 workin g days (max. 6 months ) 7 days or  next  year*Max. 6 months
Fig. 1. Implementation of directive 2011/24/EU in Poland: pre-authorization and reimbursement pathways.
Note: * If the annual reserve has been depleted.
Source: Authors.
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ay for ﬁFig. 2. Implementation of directive 2011/24/EU in Poland: pathw
Source: Authors.
onance. The rationale behind the list was to ensure that
the NHF has enough resources to guarantee access to ser-
vices to Polish patients seeking care at home. A similar
authorization is also required if the patient wishes to obtain
reimbursement of the transportation costs. Having provi-
sionally approved the application for a pre-authorization
the director may  choose to indicate a domestic provider,
who has the medical competence to perform the service
sought by the patient abroad. If it is established that the
domestic provider can indeed perform the service, the
application will be turned down [9]. Patients applying for
a pre-authorization must obtain an opinion from a medi-
cal specialist. Pre-authorization is also a condition for cost
reimbursement of selected cross-border beneﬁts. In case
of pre-authorized care, the beneﬁciary must ﬁrst cover the
full cost of cross-border care out of their pocket and then
apply for reimbursement [9].
3.2. Barrier 2: annual reimbursement limit for
cross-border care
The second barrier is the annual reimbursement limit
for cross-border care. The amendment introduces an
annual ﬁnancial reserve that can be used for reimburse-
ment of cross-border care by the NHF. The reserve applies
for the period between 2014 and 2023. When the reserve
is depleted, reimbursement is postponed until next year or
later [9].
3.3. Barrier 3: need for a referral or prescription
In order to obtain reimbursement the patient needs to
have a referral or a prescription from a Polish or other EU
doctor. While any EU doctor, including private doctors who
operate outside the statutory health systems, can provide
a referral or prescription that can be considered for reim-
bursement in Poland, among Polish doctors only those who
are contracted by the NHF may  give such referrals and pre-
scriptions [9]. This is the case in only four other member
states [5] and can be seen as the third barrier to accessing
healthcare abroad.
3.4. Barrier 4: complexity of the reimbursement process
Another barrier is the complexity of the reimbursement
process, with many formal requirements that have to be
met, and the reimbursement limits for treatments accessed
abroad. It may  take over a year to obtain reimbursement
(Fig. 1). Each application for cost reimbursement undergoes
a process of careful evaluation. Applicants must include allnancing of guaranteed beneﬁts currently not provided in Poland.
referrals, medical records and certiﬁcates. Unless issued in
English, these documents have to be translated into Polish
and – in case of drugs and medical appliances – notarized
[11]. With the exception of beneﬁts for which the rules of
coordination of social security systems apply and beneﬁts
not provided in Poland, the costs that are covered cannot
exceed the reimbursement limits established within the
Polish system. This means that if a given procedure costs
more than the reimbursement limit applied in Poland, any
excess costs will have to be covered by the patient. The
actual amount that is reimbursed will be the weighted
average of the costs of given procedure in the voivodship
(i.e. region) of patient’s residence and will thus vary across
the voivodships. This is because the voivodship branches
of the NHF negotiate prices with each provider individually
and there are no uniform prices that apply to all providers
[11]. The costs of beneﬁts not provided in Poland are paid
directly by the NHF to the provider. For Polish patients who
accessed healthcare abroad before the directive was imple-
mented the only way of obtaining reimbursement from the
NHF is through judicial action [11].
4. Health policy processes and stakeholders’
positions during directive’s implementation at the
EU level and its transposition into Polish legislation
4.1. Polish government/Ministry of Health
During the negotiations phase, Poland clearly opposed
the provisions proposed by the European Commission. The
draft directive was  strongly criticized by Ewa  Kopacz—the
Minister of Health at that time. The main cause of this
opposition was the threat that the implementation of the
directive would pose to the ﬁnancial stability of the public
payer (NHF). The Ministry of Health argued that unlimited
demand for healthcare abroad from Polish patients would
provoke uncontrolled outﬂows of money and would neg-
atively affect the contracts concluded with the national
providers and reinforce the problem of waiting lists. These
fears were shared by other member states, e.g. Malta [1]
and Spain [15].
The rulings by the ECJ cited above (e.g. Kohll and Decker
judgements), stipulated that European Community nation-
als may  obtain medical treatment in another member state
without a prior-authorization and be reimbursed in accor-
dance with the tariffs of the state in which they are insured.
This can be interpreted as giving the interests of individual
patients superiority over the interests of public payers and
reinforced the conviction of the Ministry of Health that the
implementation of the directive would have a damaging
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healthcare under the directive and also under the SocialI. Kowalska-Bobko et al. / H
ffect on the NHF’s budget [14]. Because the idea of ‘undue
elay’ was included in the draft – as it was in the ﬁnal ver-
ion of the directive – the authorities were concerned that
he large numbers of patients waiting for treatment and
iagnostic tests in Poland1 would seek treatment abroad.
he reimbursement of treatment abroad for these patients
ould be fully justiﬁed on the grounds of undue delay [13].
hat the government feared even more was that, since
he directive requires that patients are reimbursed for care
rovided by non-contracted healthcare providers abroad,
olish patients would also demand to be reimbursed for
are provided by non-contracted healthcare providers at
ome [3].
During the negotiations and the implementation stage,
he government and the Ministry of Health seemed to
verlook potential monetary beneﬁts which the imple-
entation of the directive could bring. Other countries,
uch as Malta, also focused more on damage control rather
han exploiting opportunities that cross-border healthcare
ould bring [1]. For example, Poland could be promoted as
 destination for health tourism as it has renowned medical
pecialists and relatively low costs of treatment compared
o western Europe. The directive could also lower the cost
f some publicly funded healthcare services as they could
e performed more cheaply abroad. For example, anecdo-
al evidence suggests that the cost of and waiting times for
ataract treatment in the Czech Republic are lower than in
oland. The position and actions of the Ministry of Health
ere against those of the Ministry of the Economy who
as keen to promote Poland as a destination for medical
ourism: medical tourism was included in the project “Pro-
otion of the Polish economy on international markets”
o-ﬁnanced by European Regional Development Fund [3]
nd has been promoted in a number of countries, including
he Nordic countries, Germany and the United Kingdom.
The inﬂuence of Poland and other countries that were
gainst the directive in the negotiation’s phase was not very
trong, though it has slowed down the process of it adop-
ion. The main gain from this opposition was that member
tates were allowed to implement a system of prior-
urhorizations for certain cross-border healthcare services
see Section 3), in order to avoid the risk of undermining the
lanning and/or ﬁnancing of their health system. The fears
f high costs of reimbursing cross-border care and of the
ssociated organizational and technical burden were the
ey reasons for the delay in the directive’s implementation
2]. This negative stance, shared with some other member
tates (e.g. Malta, see Ref. [1]) was reﬂected in the restric-
ive nature of the regulations transposing the directive into
olish law (see Section 3).1 According to the latest NHF data analysing waiting times for ﬁve types
f  ambulatory clinics and ﬁve types of hospital wards increased over the
013–2014 period, by up to 35% and 33%, respectively. In ambulatory care,
articularly long waiting times among the ﬁve types of ambulatory clinics
ere observed for cardiology outpatient clinics (median waiting time of
7  days with over 138 thousand patients waiting), while in inpatient care,
ongest waiting times were noted in trauma–orthopaedic wards (median
aiting time of 106 days with over 124 thousand patients waiting) [12].licy 120 (2016) 1233–1239 1237
4.2. Patients and healthcare providers
4.2.1. EU level
Other stakeholders, such as patients and healthcare
providers, were strongly in favor of the directive, both
during the negotiations at the EU level and during the trans-
position phase, and expressed this in open letters to the
Polish Members of the European Parliament (MEPs) and
the Polish Prime Minister (see Ref. [3]). For patients, the
implementation of the directive would mean faster access
to treatment, given the long waiting times for some medical
procedures in Poland, and better access to some proce-
dures, such as abortion.2 The Polish Chamber of Physicians
and Dentists hoped that the implementation of the direc-
tive would force the government to introduce long awaited
changes, such as the abolishment of administrative funding
limits by the NHF; introduction of a fair valuation of health-
care services and of a realistic estimation of the ﬁnancial
resources needed to cover the provision of the basket of
guaranteed healthcare services. These stakeholders had lit-
tle (if any) inﬂuence on the Polish MEPs and thus on the
policy process at the EU level.
4.2.2. National level
During the transposition of the directive into Polish leg-
islation, as with any other legislation, only the government
had real inﬂuence on the ﬁnal shape of the regulations and
the inﬂuence of other stakeholders was minimal. Patients
are one of the weakest stakeholder group in the healthcare
sector as they lack a strong, organized representation at
the national level. The inﬂuence of healthcare providers is
usually stronger as they are better organized and can resort
to strike actions. While the latter were overall strongly in
favor of the directive,3 the issue was  somewhat of lesser
importance to them compared to other issues of more
‘domestic’, as opposed to European, nature (such as work-
ing conditions, etc.). Apart from some attempts to exert
pressure on the Civil Rights Ombudsman to partake in the
debate on the directive, little was  done to inﬂuence the
policy process. The government was  in full control over
this process and did not enter into open discussions with
the representatives of the key stakeholders. The extremely
short time that the government foresaw for public consul-
tations (seven days), reﬂects the low inﬂuence of the public
on the policy process.
5. Accessing planned healthcare under the directive
Overall, the volume of patient mobility for plannedSecurity Regulations appears to be low [5]. This low vol-
ume seems to be due to the low number of applications
2 Directive 2011/24/EU refers to unethical treatments (amongst others)
explicitly in the 7th recital, which means that member states can exclude
those treatments from the directive’s rules (see for example Ref. [17].
3 However, they questioned some aspects of the directive. For example
the Chief Medical Chamber criticized the exclusion from reimbursement
of drugs within national drug programmes, the mechanisms for legal
recourse if a negative reimbursement decision was made, etc. See Ref.
[8] for more information.
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for reimbursement as available data suggest that approx-
imately 85% of reimbursement claims are in fact granted.
One explanation for this may  be the low awareness of EU
citizens of their cross-border rights [6].
According to the latest NHF’s data, between the 15th
of November 2014 and the 27th of March 2015 the NHF
received 777 applications for reimbursement of medical
expenses abroad amounting to approximately PLN 4.2 mil-
lion (approx. EUR 950 000). The majority of the applications
(81%) were for the reimbursement of cataract surgery,
which is a day surgery not requiring a pre-authorization.
In the ﬁrst quarter of 2015 the NHF received ten appli-
cations for planned treatment abroad that fell within the
provisions of the directive. The majority of these applica-
tions were returned to the applicants because they did not
meet the formal requirements [9].
The number of applications for the reimbursement of
cataract surgery would likely have been even greater had
the government not introduced measures to discourage
patients from seeking such treatment abroad. In 2012
reimbursement rates for cataract surgery were reduced
substantially and since cross-border healthcare is reim-
bursed according to domestic tariffs, this made going
abroad for a cataract surgery less attractive as patients
that do so could be faced with paying differences in prices
out of pocket. Moreover, statutory beneﬁts in the area
of cataract treatment were reduced, making less severe
cases of cataract not eligible for public reimbursement. This
means that only the most severe cases would qualify for
public coverage, which would dramatically reduce waiting
lists for cataract surgery, and that patients with less severe
cases of cataract would not be eligible for reimbursement
within the cross-border directive [18].
6. Conclusions
Regulations transposing the directive were clearly
meant to protect the NHF’s budget from the extra costs
of cross-border care by minimizing or postponing them.
This was to be achieved by imposing many restrictions on
the directive’s application, including requiring an obliga-
tory pre-authorization for most procedures; not allowing
non-contracted providers to issue referrals for care abroad,
imposing many formal requirements on the applications
for treatment abroad, making the application process cum-
bersome and costly and imposing a cap on the annual
budget for the reimbursement of cross-border care under
the directive.
It is difﬁcult to judge how restrictive Polish regulations
implementing the directive are compared to those put in
place in other member states. A recent (September 2015)
report by the European Commission indicates that most
member states among the 26 member states that provided
information imposed some sort of requirements restrict-
ing patient mobility [5]. For example, only seven member
states did not require a prior-authorization, while others
imposed some form of prior-authorization, ranging from
prior-authorization for a detailed list of treatments (six
member states), through prior-authorization for overnight
stay and highly specialized care (14 member states, includ-
ing Poland and Spain [15]), to prior-authorization forlicy 120 (2016) 1233–1239
everything, with the exception of one specialist consulta-
tion per patient per year (one member state). In 12 member
states, including Poland, patients must obtain a referral
from a GP or family doctor in order to access specialist
care abroad. At least four member states, including Poland,
require patients to provide a sworn translation of invoices.
It appears that government’s fears of the ‘exodus’ of Pol-
ish patients abroad have largely not materialized so far. This
is not surprising and was  expected by many analysts. Con-
sidering the cumbersome reimbursement process and the
differences in the prices of healthcare services in Poland
and in other (especially western) member states and other
costs associated with obtaining healthcare abroad, seeking
healthcare abroad is and will likely remain not affordable
to many Polish patients.
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